Inspira Technologies Reports 96% Accuracy in HYLA Blood Sensor Study

Inspira Technologies Oxy BHN ( (IINN) ) has provided an update.

On March 4, 2025, Inspira Technologies announced positive results from a clinical study of its AI-powered HYLA blood sensor, which achieved 96% accuracy in monitoring a key blood parameter. This breakthrough is expected to enhance the company’s real-time blood monitoring capabilities, potentially transforming critical care monitoring by enabling early diagnosis and personalized care without intermittent blood draws. The study, conducted at Sheba Hospital, involved six patients undergoing open-heart surgery, and the results are anticipated to support an FDA submission in the second half of 2025. The HYLA sensor targets the blood gas analyzer market and could strengthen Inspira’s position in the mechanical ventilation market.

More about Inspira Technologies Oxy BHN

Inspira Technologies Oxy B.H.N. Ltd. is a company focused on developing innovative life-support and diagnostic technologies, particularly in the respiratory support and diagnostics sector. Their flagship product, the INSPIRA ART system, aims to revolutionize critical care by enabling patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation. The company is also developing the HYLA blood sensor technology for continuous, real-time blood monitoring without the need for blood draws.

YTD Price Performance: -14.29%

Average Trading Volume: 1,232,353

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $21.83M

For an in-depth examination of IINN stock, go to TipRanks’ Stock Analysis page.